Sygnature Chemical Services and Cyprotex Establish Strategic Alliance
News Dec 10, 2009
Sygnature Chemical Services Ltd. and Cyprotex Discovery Ltd. announced they have entered into a strategic alliance. Under the terms of the agreement, Sygnature and Cyprotex will collaborate to provide a fully-integrated discovery chemistry/DMPK service to accelerate their clients’ drug discovery projects into development.
Dr Anthony Baxter, Chief Executive Offer at Cyprotex said, "We are pleased to have formed a strategic alliance with Sygnature. Over the past 5 years, they have established a reputation for high-quality medicinal chemistry, and for the intellectual input they contribute into projects. Cyprotex is known as a centre of excellence for ADME/PK services and we are the first choice CRO for many biotech and big pharma companies.
Sygnature is a centre of excellence for medicinal chemistry and has an impressive track record. By working closely together with our customers, who will be experts in their particular therapeutic project field, we are confident that we can accelerate projects forward more effectively than CROs that offer a one-stop-shop approach. My colleagues and I are looking forward to working with the Sygnature team to offer an outstanding fully-integrated discovery chemistry/ADME/DMPK service.”